A Phase 1 Dose-escalation Study of FF-10832 for Treatment of Solid Tumors Including Biliary Tract Cancer
A Phase 1 Dose-escalation Study of FF-10832 for Treatment of Solid Tumors Including Biliary Tract Cancer
Active, not recruiting · NCT03440450 · Registry updated 2026-09-02Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| A Phase 1 Dose-escalation Study of FF-10832 for Treatment of Solid Tumors Including Biliary Tract Cancer | Biliary Tract Neoplasms, Digestive System Diseases, Digestive System Neoplasms, Neoplasms by Site, biliary tract cancer, biliary tract disorder, neoplasm | Active, not recruiting | Phase 1 | 2026-09-02 | NCT03440450 |
1 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| Fujifilm Pharmaceuticals U.S.A., Inc. | 3 |
7 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| Hoag Memorial Hospital Comprehensive Cancer Center | Newport Beach | United States | 1 |
| Honor Health Research Institute | Scottsdale | United States | 17 |
| MD Anderson Cancer Research Center | Houston | United States | 2 |
| Sarah Cannon Research Institute | Nashville | United States | 119 |
| Sarah Cannon Research Institute | Denver | United States | 16 |
| University of Arizona Cancer Center | Tucson | United States | 21 |
| Virginia Mason Medical Center | Seattle | United States | 111 |